Komori

2026年3月期第2四半期(中間期)決算説明会資料

Results presentationFirst half, FY ending Mar 2026Published 2025-11-18 18:00

軟骨無形成症治療薬RBM-007のPhase 2試験で目標を達成し、Phase 3の準備と提携交渉を進める方針を示した。一方、2026年3月期第2四半期累計は研究開発費や一般管理費の増加などにより、営業損失・経常損失・当期純損失が前年同期より拡大した。

Contents of this document

Financial results presentationSecond quarter (interim period) of the fiscal year ending March 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥0 million business revenue
Operating profit¥-538 million
Ordinary income¥-513 million
Net income-514 Millions of yen profit for the period
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in R&D expenses¥11 million
  • Increase in selling, general and administrative expenses¥11 million
  • Decline in Government Grants¥-17 million
  • 受取返還金¥11 million
  • 資金運用に伴う利息の増加¥4 million
  • RBM-006費用¥42 million
  • RBM-007(CMC)費用¥-25 million
New initiatives
  • RBM-007のACH向けPhase 3の準備(2026年開始、2028年終了予定)
  • ACH治療薬について高用量・週1回皮下投与・単群試験・幼児への適応年齢引下げを想定したPhase 3計画
  • 提携パートナー候補との協議、ライセンス・アウトまたは共同開発契約の締結方針
  • DDSアプタマー技術およびアプタマー修飾LNPの開発
  • 抗TfR1アプタマー修飾LNPによる脳への核酸医薬品送達の研究
  • RBM-007を用いた糖尿病網膜症モデルでの非臨床研究
  • 第18回〜第20回新株予約権による資金調達
Key KPIsA metric the company considers important as a management benchmark.
  • Phase 2試験被験者数12 people
  • Phase 2安全性確認済み皮下投与回数500 or more times
  • Cohort 1 年間身長伸展速度の変化1.5 cm/year
  • Cohort 2 年間身長伸展速度の変化1.4 cm/year
  • RBM-007高用量投与時の年間成長速度増加率予測3 cm/year超
Market Size / Share
  • wet AMD(主要7か国)10,950 billion yen
  • 軟骨無形成症治療薬1,300 billion yen
  • Diabetic macular edema6,327 billion yen
  • Pulmonary Arterial Hypertension2,025 billion yen
  • ACH治療薬VOXZOGOの2025年売上予測900〜935
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2026
Net Sales¥0 million (business revenue)
Operating profit¥-538 million
Ordinary income¥-513 million
Net income-514 Millions of yen (profit for the period)
Breakdown of Factors Affecting the ChangeFactors Increase in R&D expenses / Amount ¥11 million, Factors Increase in selling, general and administrative expenses / Amount ¥11 million, Factors Decline in Government Grants / Amount ¥-17 million, Factors 受取返還金 / Amount ¥11 million, Factors 資金運用に伴う利息の増加 / Amount ¥4 million, Factors RBM-006費用 / Amount ¥42 million, Factors RBM-007(CMC)費用 / Amount ¥-25 million
Key KPIsIndicator name Phase 2試験被験者数 / Value 12 people / Year on year against the same period last year Not disclosed, Indicator name Phase 2安全性確認済み皮下投与回数 / Value 500 or more times / Year on year against the same period last year Not disclosed, Indicator name Cohort 1 年間身長伸展速度の変化 / Value 1.5 cm/year / Year on year against the same period last year Not disclosed, Indicator name Cohort 2 年間身長伸展速度の変化 / Value 1.4 cm/year / Year on year against the same period last year Not disclosed, Indicator name RBM-007高用量投与時の年間成長速度増加率予測 / Value 3 cm/year超 / Year on year against the same period last year Not disclosed
Market Size / ShareSubject wet AMD(主要7か国) / Market Size 10,950 billion yen, Subject 軟骨無形成症治療薬 / Market Size 1,300 billion yen, Subject Diabetic macular edema / Market Size 6,327 billion yen, Subject Pulmonary Arterial Hypertension / Market Size 2,025 billion yen, Subject ACH治療薬VOXZOGOの2025年売上予測 / Market Size 900〜935
New initiativesRBM-007のACH向けPhase 3の準備(2026年開始、2028年終了予定), ACH治療薬について高用量・週1回皮下投与・単群試験・幼児への適応年齢引下げを想定したPhase 3計画, 提携パートナー候補との協議、ライセンス・アウトまたは共同開発契約の締結方針, DDSアプタマー技術およびアプタマー修飾LNPの開発, 抗TfR1アプタマー修飾LNPによる脳への核酸医薬品送達の研究, RBM-007を用いた糖尿病網膜症モデルでの非臨床研究, 第18回〜第20回新株予約権による資金調達
Items this document does not state (21)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

2026年3月期第2四半期(中間期)決算説明会資料 | RIBOMIC Inc. (4591) timely disclosure | Komori